Join to view full profile
6400 Fannin StSte 2900Houston, TX 77030
Phone+1 713-704-3961
Fax+1 713-704-6914
Dr. Rowe is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Julie Rowe is an oncologist in Houston, TX and is affiliated with multiple hospitals in the area, including Memorial Hermann - Texas Medical Center, and Memorial Hermann Northeast. She received her medical degree from University of Texas Medical School and has been in practice 10 years. She specializes in gastrointestinal cancer.
Education & Training
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Hematology and Medical Oncology, 2010 - 2013
University of Illinois College of Medicine at ChicagoResidency, Internal Medicine, 2007 - 2010- The University of Texas Health Science Center at San AntonioClass of 2007
Certifications & Licensure
TX State Medical License 2011 - 2028
IL State Medical License 2007 - 2014
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification HealtheLife and FirstNet, Cerner Corporation, 2015-2017
- CMS Meaningful Use Stage 1 Certification Cerner Patient Portal and Powerchart, Cerner Corporation, 2015-2017
- CMS Meaningful Use Stage 2 Certification HealthSentry, Cerner Corporation, 2015-2017
Publications & Presentations
PubMed
- Comparative Effectiveness of Radiofrequency or Microwave Ablation and Chemotherapy for the Treatment of Large (>5 cm) Hepatocellular Carcinoma Tumors.Artem Boyev, Nirav Thosani, Putao Cen, Jennifer M Bailey-Lundberg, Julie Rowe
Cureus. 2026-04-01 - Consolidation enfortumab vedotin and pembrolizumab after cisplatin induction in metastatic urothelial cancer: Outcomes of complete response and bladder preservation.Kok Hoe Chan, Putao Cen, Tung Shu, Steven Canfield, Hui Zhao
The Journal of International Medical Research. 2026-03-01 - Evaluation of Prophylactic EGD versus Beta Blockade in Hepatocellular Carcinoma Patients on Anti-Angiogenic Cancer Treatments.Panayiotis D Kontoyiannis, Camila Ayerbe, Kok Hoe Chan, Sara Soliman, Victor Machicao
Journal of Hepatocellular Carcinoma. 2026-01-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
